抑郁症药物治疗的研究进展

Research Progress in Pharmacological Treatment of Major Depressive Disorder

摘要: 抑郁症作为一种高患病率、高复发率且致残性强的精神障碍，药物治疗是其核心干预手段。本文系统综述了抑郁症药物治疗的研究进展，涵盖传统药物的临床应用现状与优化策略、新型药物及疗法的突破性成果、各类药物的局限性与挑战，以及未来研究方向。传统治疗中，选择性5-羟色胺再摄取抑制剂(SSRIs)作为一线药物的疗效分层与个体化应用愈发清晰，5-羟色胺和去甲肾上腺素再摄取抑制剂(SNRIs)等二线药物的适用场景进一步明确，辅助药物的应用需严格限定适应证；新兴领域中，谷氨酸能调节剂实现了快速起效的突破，神经甾体、炎症通路调节剂等靶向新机制的药物展现出独特优势。同时，本文客观分析了各类药物在不良反应、使用障碍及证据层面的局限。未来研究需聚焦生物标志物指导的精准治疗、联合治疗策略优化及特殊人群治疗方案探索，以应对当前药物完全缓解率低、起效延迟、个体差异显著等挑战，推动抑郁症治疗迈向多靶点协同与个体化精准干预的新时代。

Abstract: Major depressive disorder (MDD), a mental disorder with high prevalence, high recurrence rate, and strong disability, relies heavily on pharmacological treatment as its core intervention. This article systematically reviews the research progress in pharmacological treatment of MDD, covering the clinical application status and optimization strategies of traditional drugs, breakthrough achievements of new drugs and therapies, limitations and challenges of various drugs, as well as future research directions. In traditional treatment, the efficacy stratification and individualized application of selective serotonin reuptake inhibitors (SSRIs) as first-line drugs have become increasingly clear; the applicable scenarios of second-line drugs such as serotonin-norepinephrine reuptake inhibitors (SNRIs) have been further clarified; and the application of adjuvant drugs needs to be strictly limited to specific indications. In the emerging field, glutamatergic modulators have achieved a breakthrough in rapid onset of action, and drugs targeting new mechanisms such as neurosteroids and inflammatory pathway modulators have shown unique advantages. At the same time, this article objectively analyzes the limitations of various drugs in terms of adverse reactions, use barriers and evidence. Future research should focus on biomarker-guided precision treatment, optimization of combination therapy strategies, and exploration of treatment regimens for special populations, to address challenges such as low complete remission rate, delayed onset, and significant individual differences of current drugs, and promote MDD treatment towards an era of multi-target synergy and individualized precision intervention.